**S2 Text. Grading system for the quality of the papers included in the analysis**

**Detailed demographic information: Max points: 11**

* Average age stated: 0, 1
* Gender mentioned: 0, 1
* Study design mentioned: 1, 2
  + Retrospective cohort: 1
  + Prospective cohort: 2
* Race mentioned: 0,1
* Stage or grade percentages reported: 0,1
* Treatment modalities available at facility mentioned: 0,1
* Receptor status percentages reported: max points 4
  + ER: 0, 1
  + PR: 0, 1
  + Her2/Neu: 0, 1
  + TNBC: 0, 1

**Stratified reporting of survival: Max Points: 7**

* 5-year survival reported: max points 2
  + Kaplan-Meier estimation: 1
  + Through direct 5-year patient follow-up: 2
* Survival by stage or grade reported: 0, 1
* Survival by receptor status reported: max points 4
  + ER: 0, 1
  + PR: 0, 1
  + Her2/Neu: 0, 1
  + TNBC: 0, 1

**Sample size: Max points: 6**

* Overall sample size: max points 3
  + less than 50: 1
  + 50-150: 2
  + greater than 150: 3
* Percentage of patients with successful follow-up: max points 3
  + Less than 50%: 1
  + 50-75%: 2
  + Greater than 75%: 3

**Total max score from three domains: 24**